import Link from "next/link";
import JsonLd from "@/components/JsonLd";

export const metadata = {
  alternates: { canonical: "/compare/semaglutide-vs-tirzepatide" },
  title: "Semaglutide vs Tirzepatide — GLP-1 Comparison | Prof. Peptide",
  description:
    "Semaglutide vs Tirzepatide comparison — mechanism, weight loss data, FDA approval status, side effects, and key clinical trial results.",
};

const rows = [
  ["Mechanism", "GLP-1 receptor agonist (single agonist)", "Dual GLP-1 + GIP (glucose-dependent insulinotropic polypeptide — works with GLP-1 to enhance insulin response) receptor agonist"],
  ["Brand Names", "Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral)", "Mounjaro (diabetes), Zepbound (obesity)"],
  ["FDA Approval", "Diabetes: 2017. Obesity (Wegovy): 2021", "Diabetes: 2022. Obesity (Zepbound): 2023"],
  ["Average Weight Loss", "10\u201315% body weight (Wegovy trials)", "15\u201322% body weight (Zepbound/SURMOUNT trials)"],
  ["Head-to-Head Data", "SURMOUNT-5 (2025, NEJM): Tirzepatide superior", "Same trial \u2014 ~47% more weight loss than semaglutide at 72 weeks"],
  ["GI Side Effects", "Nausea, vomiting, diarrhea \u2014 common, usually transient", "Similar profile \u2014 some evidence of fewer GI side effects at higher doses"],
  ["Dosing", "Once weekly subcutaneous (or daily oral for Rybelsus)", "Once weekly subcutaneous injection"],
  ["Blood Sugar Control", "Reduces HbA1c (a 3-month blood sugar marker) 1\u20132%", "Reduces HbA1c 2\u20132.5% (stronger glucose control)"],
  ["Cardiovascular Data", "SUSTAIN-6, SELECT trials \u2014 significant CV risk reduction", "SURPASS-CVOT \u2014 cardiovascular outcomes trial ongoing"],
  ["Research Status", "Most studied GLP-1 agonist \u2014 extensive long-term data", "Newer \u2014 strong Phase 3 data, long-term data still accumulating"],
];

export default function SemaglutideVsTirzepatidePage() {
  return (
    <>
      <JsonLd data={{"@context":"https://schema.org","@type":"Article","headline":"Semaglutide vs Tirzepatide — GLP-1 Comparison","description":"Semaglutide vs Tirzepatide comparison — mechanism, weight loss data, FDA approval status, side effects, and key clinical trial results.","url":"https://profpeptide.com/compare/semaglutide-vs-tirzepatide","publisher":{"@type":"Organization","name":"Prof. Peptide","url":"https://profpeptide.com"}}} />
      <JsonLd data={{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://profpeptide.com"},{"@type":"ListItem","position":2,"name":"Comparisons","item":"https://profpeptide.com/compare"},{"@type":"ListItem","position":3,"name":"Semaglutide vs Tirzepatide — GLP-1 Comparison"}]}} />
    <div className="section max-w-4xl">
      <Link href="/compare" className="text-sm text-[#0891b2] hover:underline mb-6 inline-block">&larr; Back to Comparisons</Link>
      <h1 className="text-3xl font-bold text-[#1e2d3d] dark:text-slate-100 mb-3">Semaglutide vs Tirzepatide &mdash; GLP-1 Peptide Comparison</h1>
      <p className="text-sm text-gray-500 dark:text-slate-400 leading-relaxed mb-8 max-w-2xl">Semaglutide and Tirzepatide are the two most clinically significant metabolic peptides of the past decade. Both are FDA-approved and backed by large-scale Phase 3 trials. Tirzepatide is newer and shows greater average weight loss, but semaglutide has a longer track record and broader approval history.</p>

      <div className="mb-8 p-5 border border-[#0891b2]/20 bg-[#0891b2]/10 rounded-xl">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-3">Why GLP-1 receptor activation matters</h2>
        <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed mb-3">
          GLP-1 (glucagon-like peptide-1) is a hormone naturally released from the gut after eating. It does three things at once: it slows gastric emptying so you feel full longer, it triggers insulin release to manage blood sugar, and it acts on the hypothalamus to reduce appetite.
        </p>
        <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed mb-3">
          Both semaglutide and tirzepatide are synthetic peptides engineered to activate this receptor at a much higher intensity and for far longer than natural GLP-1 &mdash; which lasts only minutes. Semaglutide activates GLP-1 alone. Tirzepatide adds GIP receptor activation on top, which further improves insulin sensitivity and may reduce nausea side effects compared to GLP-1 alone.
        </p>
        <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
          The shared GLP-1 mechanism is why both medications produce similar core effects (reduced appetite, weight loss, better blood sugar) &mdash; and why they share the same GI side effect profile.
        </p>
      </div>

      <div className="overflow-x-auto mb-8">
        <table className="w-full text-sm border-collapse">
          <thead>
            <tr className="bg-gray-50 dark:bg-[#1e293b]">
              <th className="text-left px-4 py-3 font-semibold text-gray-400 dark:text-slate-500 text-xs uppercase tracking-wider border-b border-gray-100 dark:border-slate-700 w-1/4"></th>
              <th className="text-left px-4 py-3 font-semibold text-[#0891b2] text-xs uppercase tracking-wider border-b border-gray-100 dark:border-slate-700 w-[37.5%]">Semaglutide</th>
              <th className="text-left px-4 py-3 font-semibold text-[#0891b2] text-xs uppercase tracking-wider border-b border-gray-100 dark:border-slate-700 w-[37.5%]">Tirzepatide</th>
            </tr>
          </thead>
          <tbody>
            {rows.map(([label, a, b], i) => (
              <tr key={i} className={i % 2 === 0 ? "bg-white dark:bg-[#0f172a]" : "bg-gray-50/50 dark:bg-slate-800/50"}>
                <td className="px-4 py-3 font-medium text-[#1e2d3d] dark:text-slate-100 border-b border-gray-100 dark:border-slate-700">{label}</td>
                <td className="px-4 py-3 text-gray-600 dark:text-slate-300 border-b border-gray-100 dark:border-slate-700">{a}</td>
                <td className="px-4 py-3 text-gray-600 dark:text-slate-300 border-b border-gray-100 dark:border-slate-700">{b}</td>
              </tr>
            ))}
          </tbody>
        </table>
      </div>

      <div className="mb-8">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Which one is right for you?</h2>
        <p className="text-sm text-gray-500 dark:text-slate-400 leading-relaxed mb-4">
          This is general framing for educational purposes &mdash; the actual decision should involve your prescribing physician. Insurance coverage, BMI thresholds, and individual health history all matter.
        </p>
        <div className="space-y-4">
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">First time considering GLP-1 therapy</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Semaglutide is the most-studied option with the longest safety record (FDA-approved 2017 for diabetes, 2021 for obesity). It&apos;s the natural starting point for most patients new to this class. Available as Ozempic (diabetes), Wegovy (obesity), or Rybelsus (oral form).
            </p>
          </div>
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Currently on semaglutide and want stronger results</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Tirzepatide showed about 47% greater weight loss than semaglutide in the SURMOUNT-5 head-to-head trial &mdash; roughly 22.5% body weight reduction vs 14.9% over 72 weeks. The dual GLP-1/GIP mechanism is responsible for the stronger output. Most patients who plateau on semaglutide find tirzepatide produces meaningful additional progress.
            </p>
          </div>
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Have type 2 diabetes plus obesity</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Both are FDA-approved for both conditions. Tirzepatide has slightly stronger HbA1c reduction (~2&ndash;2.5% vs ~1&ndash;2%) and stronger weight loss. Semaglutide may be preferred where insurance coverage favors Ozempic/Wegovy. The choice often comes down to insurance approval as much as clinical efficacy.
            </p>
          </div>
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Prioritize long-term safety data</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Semaglutide has 8+ years of post-market data (approved 2017). Tirzepatide has 4+ years (approved 2022). For patients prioritizing the longest established safety record, semaglutide remains the first choice. Tirzepatide&apos;s safety profile so far is favorable but the body of long-term real-world data is still building.
            </p>
          </div>
        </div>
      </div>

      <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5 mb-8">
        <h2 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Bottom Line</h2>
        <p className="text-sm text-gray-600 dark:text-slate-300">Tirzepatide produces greater average weight loss and better blood sugar control in head-to-head data. <Link href="/peptides/semaglutide" className="text-[#0891b2] hover:underline">Semaglutide</Link> has a longer track record, broader approval history, and more long-term safety data. Both are prescription medications, but both are also widely available as research-grade peptides through specialty vendors. See <Link href="/coupons" className="text-[#0891b2] hover:underline">Verified Discount Codes</Link> for current options.</p>
      </div>

      <div className="mb-8">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-4">FAQ</h2>
        <div className="space-y-4">
          <div>
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">Is there a generic version of either medication?</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Not in the US. Both semaglutide and tirzepatide remain on-patent through Eli Lilly and Novo Nordisk respectively. Compounded versions are sold through some online pharmacies and weight-loss clinics, but the FDA has issued warnings about quality and safety of compounded GLP-1 products. For commercial brand-name medications, expect to pay full retail unless your insurance covers them.
            </p>
          </div>
          <div>
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">Why do they cause GI side effects?</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              GLP-1 receptors are present throughout the gut. Activating them slows gastric emptying &mdash; food sits in the stomach longer, which is how they make you feel full. The slowed emptying is also what causes nausea, vomiting, and constipation in many patients, especially during dose escalation. Side effects usually decrease as the body adjusts to each dose level over 4&ndash;8 weeks.
            </p>
          </div>
          <div>
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">How long do you have to take them?</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              For weight loss: indefinitely, in most cases. Studies show that stopping the medication leads to most of the lost weight returning over 1&ndash;2 years. For diabetes management: typically lifelong as part of comprehensive diabetes care, similar to how other diabetes medications are used. The &ldquo;weight loss medication&rdquo; framing implies a temporary intervention, but the clinical reality is more like ongoing therapy.
            </p>
          </div>
          <div>
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">How does insurance coverage compare?</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Coverage varies dramatically by plan and indication. Most insurers cover both medications for type 2 diabetes (Ozempic, Mounjaro). Coverage for the obesity-specific brands (Wegovy, Zepbound) is more restricted &mdash; many plans deny coverage or require BMI &ge;30 plus a comorbidity. Patients with both diabetes and obesity often have an easier path to coverage. Cash prices are roughly $1,000&ndash;1,400/month without coverage.
            </p>
          </div>
          <div>
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">Can you switch between semaglutide and tirzepatide?</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Yes, switching is common and safe under physician supervision. Most clinicians recommend a 1&ndash;2 week washout period when switching to avoid additive side effects, then starting the new medication at its lowest dose for re-titration. Patients should not switch on their own without medical guidance.
            </p>
          </div>
          <div>
            <h3 className="text-sm font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">What about the &ldquo;research peptide&rdquo; versions sold online?</h3>
            <p className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
              Research-grade semaglutide and tirzepatide are sold as &ldquo;for research use only&rdquo; by some peptide vendors. These are not FDA-approved and are not legally for human use. Quality varies dramatically by source, and there&apos;s no clinical infrastructure for dose titration, side effect management, or safety monitoring. The FDA has issued warnings against using these for weight loss. PP does not recommend research-grade GLP-1s for human use.
            </p>
          </div>
        </div>
      </div>

      <div className="flex gap-3 mb-8">
        <Link href="/peptides/semaglutide" className="btn-primary text-sm">Semaglutide Profile</Link>
        <Link href="/peptides/tirzepatide" className="btn-outline text-sm">Tirzepatide Profile</Link>
      </div>

      <p className="text-xs text-gray-400 dark:text-slate-500 leading-relaxed">For educational and research purposes only. Not medical advice.</p>
    </div>
    </>
  );
}
